Targeting cancer cells by exploiting their resistance (Q35192546)

7 August 2017

1 reference

title

Targeting cancer cells by exploiting their resistance (English)

1 reference

7 August 2017

1

Mikhail V Blagosklonny

1 reference

7 August 2017

publication date

1 July 2003

1 reference

Trends in Molecular Medicine

7 August 2017

published in

1 reference

7 August 2017

volume

9

1 reference

7 August 2017

issue

7

1 reference

7 August 2017

page(s)

307-312

1 reference

Perspectives on the development of a molecularly targeted agent

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Apoptosis in cancer therapy: crossing the threshold

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

P53, cell cycle control and apoptosis: Implications for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Integrating genetic approaches into the discovery of anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Choosing anticancer drug targets in the postgenomic era.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Multidrug resistance in cancer: role of ATP-dependent transporters

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Apoptosis-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Effect of P-glycoprotein on flavopiridol sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Neuroprotection by a caspase inhibitor in acute bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Prevention of lymphocyte cell death in sepsis improves survival in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Peptidomimetic fluoromethylketone rescues mice from lethal endotoxic shock.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Caspase-1-inhibitor ac-YVAD-cmk reduces LPS-lethality in rats without affecting haematology or cytokine responses

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Caspase inhibitors prevent cisplatin-induced apoptosis of auditory sensory cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

The caspase inhibitor z-VAD is more effective than CD18 adhesion blockade in reducing muscle ischemia-reperfusion injury: implication for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Caspase inhibition by Z-VAD increases the survival of grafted bone marrow cells and improves functional outcome after MCAo in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Inhibition of myocardial apoptosis as a therapeutic target in cardiovascular disease prevention: focus on caspase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Caspase inhibitors as anti-inflammatory and antiapoptotic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Cell cycle phase-specific chemotherapy: computational methods for guiding treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

1 reference

7 January 2021

Microtubules and actin filaments: dynamic targets for cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Drug-resistance enables selective killing of resistant leukemia cells: exploiting of drug resistance instead of reversal.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Requirement for p53 and p21 to sustain G2 arrest after DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Disruption of p53 in human cancer cells alters the responses to therapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Inhibiting the p53-MDM2 interaction: an important target for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Flavopiridol inversely affects p21(WAF1/CIP1) and p53 and protects p21-sensitive cells from paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Selective killing of transformed baby hamster kidney (BHK) cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Apoptosis in anititumor strategies: Modulation of cell cycle or differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Role reversal for anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Cyclotherapy: protection of normal cells and unshielding of cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

A new science-business paradigm in anticancer drug development.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

Oncogenic resistance to growth-limiting conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2803%2900111-4

7 January 2021

10.1016/S1471-4914(03)00111-4

Identifiers

DOI

1 reference

7 August 2017

1 reference